Anavex Life Sciences Corp. (AVXL) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 2.73 |
| Open | 2.66 |
| Day High | 2.8 |
| Day Low | 2.53 |
| 52-Week High | 13.99 |
| 52-Week Low | 2.41 |
| Volume | 1.12M |
| Average Volume | 1.49M |
| Market Cap | 235.39M |
| PE | -5.52 |
| EPS | -0.46 |
| Moving Average 50 Days | 3.01 |
| Moving Average 200 Days | 5.01 |
| Change | -0.19 |
Anavex Life Sciences to Present at the Citizens Life Sciences Conference
GlobeNewswire Inc.
Mar 03, 2026 12:30 PM GMT
NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease,
Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference
GlobeNewswire Inc.
Feb 25, 2026 12:30 PM GMT
NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease,
Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors
GlobeNewswire Inc.
Feb 23, 2026 12:30 PM GMT
NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease,